Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refr...

Celý popis

Podrobná bibliografia

Vydané v:	Journal of clinical oncology Ročník 30; číslo 18; s. 2183
Hlavní autori:	Younes, Anas, Gopal, Ajay K, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Ramchandren, Radhakrishnan, Bartlett, Nancy L, Cheson, Bruce D, de Vos, Sven, Forero-Torres, Andres, Moskowitz, Craig H, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Kennedy, Dana A, Sievers, Eric L, Chen, Robert
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 20.06.2012
Predmet:	Adolescent Adult Aged Antineoplastic Agents - therapeutic use Disease-Free Survival Female Hodgkin Disease - drug therapy Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Male Middle Aged Recurrence Young Adult
ISSN:	1527-7755, 1527-7755
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!